

ASX Release

Share Purchase Plan (SPP) results

SPP for eligible shareholders that closed Wednesday 18th December 2024 at 5.00PM (AEDT) raised \$274,500

ADELAIDE, 20th December 2024: Anatara Lifesciences Ltd (ASX: ANR or Anatara or “the Company”), a developer of evidence-based solutions for gastrointestinal diseases in humans, is pleased to provide details of the Share Purchase Plan (“SPP”) uptake that closed at 5PM AEDT on 18th December 2024.

The SPP raised a total of \$274,500.00 which complemented the Company’s recent placement to institutional and sophisticated investors which raised \$750,000 (before costs) (“Placement”)

Anatara announced a Placement and an SPP on the 15th of November 2024. The Company’s intent with the SPP was to provide an equitable opportunity for existing shareholders to purchase shares on the same terms as institutional and sophisticated investors. Eligible shareholders who held shares on the record date of 14th of November were eligible to purchase shares in the Company at \$0.05 each in amounts from a minimum of \$2,000 to a maximum \$30,000 to support the Company (with no fees or transaction costs). The SPP closed at 5PM AEDT on Wednesday the 18th of December 2024. The full share applications from the SPP are scheduled for allotment on Monday 23 December 2024.

Anatara Executive Chair Dr. David Brookes commented, *“The pleasing response to the SPP, combined with the Placement, means Stage 2 of the IBS trial and the new anti-obesity project are now funded beyond milestones that are important inflection points. On behalf of the Company, we thank those that participated in the capital raise for their ongoing support.”*

As stated previously, the funds raised from the Placement and the SPP will be used to complete the pivotal Phase II clinical study of Anatara’s GaRP (Gastrointestinal ReProgramming) complementary medication for irritable bowel syndrome (IBS) and to further readiness for manufacturing. There will also be approximately \$250,000 allocated to an anti-obesity proof of concept project. The anti-obesity project has been designed to develop an oral medication to assist with weight reduction and sustaining weight control, in conjunction with other contemporary treatments and approaches.

About GaRP

Anatara’s GaRP product is a multi-component, multi-coated complementary medicine designed to address underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD. GaRP is the working name for the product from the Company’s **Gastrointestinal ReProgramming** project that was designed to assist restoration and maintenance of the gastrointestinal tract (GIT) lining as a barrier and assist the homeostasis of the microbiome. The product is made of GRAS (Generally Regarded As Safe) components.



This announcement was authorised for release on the ASX by Anatara Lifesciences Ltd Executive Chair, Dr. David Brookes, with Board approval.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

Dirk van Dissel
Candour Advisory – Investor Relations
+61 (0) 408 326 367
dirk@candouradvisory.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited

Registered Office

C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000

Email info@anatara.com | Website anataralifesciences.com

